At Angiotech, we are redefining success by striving to create novel medical solutions that elevate the standard of care and improve people's lives.
Angiotech is Redefining Success
- Angiotech is a global specialty pharmaceutical and medical device company that discovers, develops, and markets innovative technologies and medical products primarily for local diseases or for complications associated with medical device implants, surgical interventions and acute injury. We are listed on both the TSX and NASDAQ stock exchanges (NASDAQ: ANPI, TSX: ANP). Read More...
If you are a Healthcare Professional and would like to learn more about Angiotech's products, please visit AngioEduPRO.com; Angiotech's Educational Resource for Healthcare Professionals.
Press Releases
- March 16 - Study Shows Superior Efficacy for TAXUS® Express® Stents at One Year Compared to Bare-Metal Stents in Diabetic Patients Experiencing Heart Attack Read More...
- March 15 - Angiotech Pharmaceuticals Announces PERSEUS Trial Results Demonstrate Positive Safety and Efficacy Outcomes for Boston Scientific's Novel Platinum Chromium TAXUS® Element™ Stent System Read More...
- All Press Releases
Highlights
- Financial Results for the Fourth Quarter Ended December 31, 2009 View Now...
- Angiotech's 2009 Annual General Meeting Presentation View Now...
